RO130470A2 - Formula for suppositories for prostatitis treatment - Google Patents
Formula for suppositories for prostatitis treatment Download PDFInfo
- Publication number
- RO130470A2 RO130470A2 ROA201300927A RO201300927A RO130470A2 RO 130470 A2 RO130470 A2 RO 130470A2 RO A201300927 A ROA201300927 A RO A201300927A RO 201300927 A RO201300927 A RO 201300927A RO 130470 A2 RO130470 A2 RO 130470A2
- Authority
- RO
- Romania
- Prior art keywords
- dose
- extract
- tincture
- oil
- suppositories
- Prior art date
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 6
- 201000007094 prostatitis Diseases 0.000 title abstract description 3
- 229940098465 tincture Drugs 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims abstract description 5
- 235000019198 oils Nutrition 0.000 claims abstract description 5
- 241000241413 Propolis Species 0.000 claims abstract description 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000008390 olive oil Nutrition 0.000 claims abstract description 4
- 239000004006 olive oil Substances 0.000 claims abstract description 4
- 229940069949 propolis Drugs 0.000 claims abstract description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims abstract description 4
- 235000002020 sage Nutrition 0.000 claims abstract description 4
- 229960003232 troxerutin Drugs 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 241000693818 Helleborus purpurascens Species 0.000 claims abstract description 3
- 239000006286 aqueous extract Substances 0.000 claims abstract description 3
- 229940002386 calendula officinalis extract Drugs 0.000 claims abstract description 3
- 239000010668 rosemary oil Substances 0.000 claims abstract description 3
- 229940058206 rosemary oil Drugs 0.000 claims abstract description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 235000019480 chamomile oil Nutrition 0.000 claims description 4
- 239000010628 chamomile oil Substances 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- 244000003240 Caesalpinia gilliesii Species 0.000 claims description 3
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 230000008578 acute process Effects 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 235000011472 cat’s claw Nutrition 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 235000020759 St. John’s wort extract Nutrition 0.000 abstract 1
- 240000002299 Symphytum officinale Species 0.000 abstract 1
- 235000005865 Symphytum officinale Nutrition 0.000 abstract 1
- 229940119217 chamomile extract Drugs 0.000 abstract 1
- 235000020221 chamomile extract Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940099416 st. john's wort extract Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 3
- 240000001432 Calendula officinalis Species 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229940065811 helleborus extract Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- -1 witepsol Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Formulă de supozitoare pentru tratamentul prostatitelor Zanoschi Christache, Str. Pinului, nr.9, IașiFormula of suppositories for the treatment of prostatitis Zanoschi Christache, Str. Pinului, no.9, Iași
Prezenta invenție se referă la o formulă terapeutică pentru tratamentul adjuvant al proceselor inflamatorii acute și cronice ale prostatei.The present invention relates to a therapeutic formula for the adjuvant treatment of acute and chronic inflammatory processes of the prostate.
în literatură sunt cunoscute numeroase produse naturale sau chimice pentru tratamentul proceselor inflamatorii ale prostatei.Numerous natural or chemical products for the treatment of inflammatory processes of the prostate are known in the literature.
Acestea prezintă dezavantajul unei acțiuni incomplete, fapt care nu duce la vindecarea proceselor inflamatorii ale prostatei.These have the disadvantage of an incomplete action, which does not heal the inflammatory processes of the prostate.
Prezenta formulă terapeutică vine să corecteze aceste dezavantaje prin aceea că este constituită din troxerutin 0,015-0,125g/doză, de preferat 0,025g, extract uleios de mușețel 0,015-0,125g/doză, de preferat O,O55g, extract uleios de sunătoare 0,115-0,125g/doză, de preferat 0,100g, extract de calendula officinalis 0,015-0,125g/doză, de preferat 0,125g, ulei de rozmarin 0,015-0,125g/doză, de preferat 0,075g, ulei de cătină 0,015-0,125g/doză, de preferat 0,075g, ulei de măsline 0,115-0,125g/doză, de preferat 0,100g, vitamina E (lOOOui) 0,1150,125g/doză, de preferat 0,05g, extract apos de Helleborus purpurascens 0,1150,125g/doză, de preferat 0,025g, lanolină 0,115-0,125g/doză, de preferat 0,100g, ceară galbenă 0,115-0,125g/doză, de preferat 0,100g, colesterol 0,037-0,057g/doză, de preferat 0,037g, polidocanol 0,037-0,057g/doză, de preferat 0,037g, tinctură de propolis 0,05-0.09g/doză, de prefarat 0,05g, tinctură de salvie 0,115-0,125g/doză, de preferat 0,1 OOg, tinctură de tătăneasă 0,115-0,125g/doză, de preferat 0,1 OOg, alantoină 0,115-0,125g/doză, de preferat 0,025g, cat’s claw 0,037-0,057g/doză, de preferat 0,037, lactoză și rășină (în proporții egale) 0,037-0,057g/doză, de preferat 0,037g, polisorbat 80 0,062-0,026, de preferat 0,062, witepsol 1,182-1,245, de preferat 1,182gThe present therapeutic formula corrects these disadvantages by the fact that it consists of troxerutin 0.015-0.125g / dose, preferably 0.025g, chamomile oil extract 0.015-0.125g / dose, preferably O, O55g, 0.115- 0.125g / dose, preferably 0.100g, calendula officinalis extract 0.015-0.125g / dose, preferably 0.125g, rosemary oil 0.015-0.125g / dose, preferably 0.075g, seafood oil 0.015-0.125g / dose , preferably 0.075g, olive oil 0.115-0.125g / dose, preferably 0.100g, vitamin E (lOOOui) 0.1150.125g / dose, preferably 0.05g, aqueous extract of Helleborus purpurascens 0.1150.125g / dose, preferably 0.025g, lanolin 0.115-0.125g / dose, preferably 0.100g, yellow wax 0.115-0.125g / dose, preferably 0.100g, cholesterol 0.037-0.057g / dose, preferably 0.037g, polydocanol 0.037 -0.057g / dose, preferably 0.037g, propolis tincture 0.05-0.09g / dose, preferably 0.05g, sage tincture 0.115-0.125g / dose, preferably 0.1 O Og, tinctured tincture 0.115-0.125g / dose, preferably 0.1 OOg, allantoin 0.115-0.125g / dose, preferably 0.025g, cat's claw 0.037-0.057g / dose, preferably 0.037, lactose and resin (in equal proportions) 0.037-0.057g / dose, preferably 0.037g, polysorbate 80 0.062-0.026, preferably 0.062, witepsol 1.182-1.245, preferably 1.182g
Mai jos se dă un exemplu de realizare a invenției.The following is an example of an embodiment of the invention.
într-un reactor se omogenizează vitamina E, witepsol, lanolină, ceară galbenă, colesterolul și polidocanolul și se obține faza A.Tincturile de propolis, salvie și tătăneasă se evaporă 35% din ele pentru îndepărtarea alcoolului și rezultă faza B. în faza B se dizolvă troxerutinul și rezultă faza C. Se anmestecă în alt recipient extractul uleios de mușețel cu extracctul uleios de sunătoare, extractul de calendula officinalis, uleiul de cătină, uleiul de rozmarin și uleiul de măsline și rezultă faza D. Peste faza A se adaugă faza D și apoi extractul de helleborus,Vitamin E, witepsol, lanolin, yellow wax, cholesterol and polydocanol are homogenized in a reactor and phase A. The propolis, sage and tuna tinctures are evaporated and 35% evaporated to remove alcohol and result in phase B. dissolve the troxerutin and result in phase C. Mix the chamomile oil with the extract of the chamomile oil, the extract of calendula officinalis, the extract of calendula officinalis, the oil of rosin and the oil of rosemary and the olive oil in another container and the result of phase D. Add phase P and then the helleborus extract,
Cl· 2 ΰ 1 3 00927-2 fl -11- 2013 polisorbatul, alantoina, cat’s claw, lactoza și rășina; după omogenizare se adaugă faza C și apoi se toarnă în supozitoare.Cl · 2 ΰ 1 3 00927-2 on -11- 2013 polysorbate, allantoin, cat's claw, lactose and resin; after homogenization, phase C is added and then poured into suppositories.
Supozitoarele astfel obținute prezintă sunt recomandate pentru tratamentul proceselor inflamatorii acute și cronice ale prostatei.The suppositories thus obtained are recommended for the treatment of acute and chronic inflammatory processes of the prostate.
BibliografieBibliography
Ursula Stănescu, Anca Miron, monica Hăncianu, Clara Aprotooaie: Plante medicinale de la A la Z (monografii ale produselor de interes terapeutic), voi I și voi II, Editura „Gr. T. Popa”, UMF Iași, 2004Ursula Stanescu, Anca Miron, monica Hăncianu, Clara Aprotooaie: Medicinal plants from A to Z (monographs of products of therapeutic interest), you I and you II, "Gr. T. Popa ”, UMF Iași, 2004
Mirică Ecaterina. Tehnologia produselor cosmetice, voi I, substanțe active și aditivi, editura Lolos, 2oo3Mirică Ecaterina. The technology of cosmetic products, I, active substances and additives, Lolos publishing house, 2oo3
Mencinicopschi Gh., Bujor O,Ionescu Călinești L.:compendiu de terapie naturală, Editura Medicală, 2009Mencinicopschi Gh., Bujor O, Ionescu Călinești L.: Compendium of natural therapy, Medical Publishing House, 2009
Popovici Iuliana, Lupuleasa Dumitru, Tehnologie Farmaceutică, voi I și III, Editura Polirom, Iași, 2009Popovici Iuliana, Lupuleasa Dumitru, Pharmaceutical Technology, I and III, Polirom Publishing House, Iași, 2009
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ROA201300927A RO130470B1 (en) | 2013-11-28 | 2013-11-28 | Troxerutin-based suppositories for prostatitis treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ROA201300927A RO130470B1 (en) | 2013-11-28 | 2013-11-28 | Troxerutin-based suppositories for prostatitis treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RO130470A2 true RO130470A2 (en) | 2015-08-28 |
| RO130470B1 RO130470B1 (en) | 2018-11-29 |
Family
ID=53939493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ROA201300927A RO130470B1 (en) | 2013-11-28 | 2013-11-28 | Troxerutin-based suppositories for prostatitis treatment |
Country Status (1)
| Country | Link |
|---|---|
| RO (1) | RO130470B1 (en) |
-
2013
- 2013-11-28 RO ROA201300927A patent/RO130470B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RO130470B1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarkar et al. | Ameliorative effects of oleanolic acid on fluoride induced metabolic and oxidative dysfunctions in rat brain: experimental and biochemical studies | |
| EA201800367A1 (en) | METHODS OF TREATMENT OF HUNTINGTON'S DISEASE | |
| MX2020010603A (en) | Hemp extract for treatment of pain in animals. | |
| EA201790951A1 (en) | DERIVATIVES OF HYDROXYLKYL SUBSTITUTED PHENILTRIASOLE AND THEIR USE | |
| RU2015149680A (en) | AGENTS TO SUPPRESS ACTIVITY AND / OR REDUCE THE NUMBER OF BCL-XL AND / OR BCL-W | |
| EA201691845A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| RU2016135431A (en) | COMPOSITION FOR LOCAL TREATMENT OF THE RAS | |
| EA201592068A1 (en) | INHANSER INHIBITORS ZESTE HOMOLOGIST 2 | |
| EA201591327A1 (en) | SUBSTITUTED PYRROPOLYRIMIDIN COMPOUNDS, THEIR COMPOSITIONS AND TREATMENT METHODS USING SUCH CONNECTIONS | |
| EA201691844A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| EA201890198A1 (en) | NEW PROTEINS SPECIFIC FOR THE LAG-3 | |
| MX2018004043A (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids. | |
| EA201791898A1 (en) | NEW ANTIBODIES CONNECTING WITH TFPI AND CONTAINING THEIR COMPOSITION | |
| MX382357B (en) | METHODS AND COMPOSITIONS FOR TREATING SKIN FUNGAL INFECTIONS. | |
| EA201691962A1 (en) | AMIDOSED NITROGEN COMPOUNDS AS TNKS1 AND / OR TNKS2 INHIBITORS | |
| BR112013005532A2 (en) | therapeutic agent for pain | |
| RO130470A2 (en) | Formula for suppositories for prostatitis treatment | |
| EA202090666A1 (en) | APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY | |
| MX381545B (en) | TRIAZOLES FOR THE REGULATION OF INTRACELLULAR CALCIUM HOMEOSTASIS. | |
| RO130471A2 (en) | Antihemorrhoidal suppositories | |
| ES2576777A1 (en) | Composition for the treatment of skin diseases and for veterinary use (Machine-translation by Google Translate, not legally binding) | |
| EA201490478A1 (en) | METHOD OF GETTING DRY EXTRACTS | |
| RU2018104859A (en) | A HERBAL MEDICINE FOR TREATMENT OF RAS AND ITS APPLICATION | |
| RU2013143063A (en) | PERFUMERY AND COSMETIC PRODUCT "BIOTERMAL" FOR CARE OF NORMAL AND DRY SKIN | |
| RO130472A2 (en) | Hemorrhoid treatment cream |